Engineered lactococcus lactis secreting flt3l and ox40 ligand for in situ vaccination-based cancer immunotherapy

HIGHLIGHTS

• who: Junmeng Zhu from the Reagents, bacterial strains, cell lines, and mice Lactococcus lactis , and p, vector were obtained from MoBiTec (Germany)Escherichia coli , (DE3) was purchased from Shanghai Weidi Biotechnology Co, Ltd. Escherichia coli strains were incubated in Luria-Bertani (LB) medium at , u00b0C with shaking at , rpm. Lactis , was propagated statically in , (Difco) medium containing, .5% (w/v) glucose (GM17) at , u00b0C. B, and , cells were obtained from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology. , CT26-GFP-Luc colon cancer cells, MC38-GFP-Luc colon cancer cells, GFP-Luc breast cancer . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.